Skip to main content

Peer Review reports

From: Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER + HER2 − Rb wild-type and knock-down in breast cancer cell lines

Original Submission
4 May 2020 Submitted Original manuscript
4 Sep 2020 Author responded Author comments - Oliviero Marinelli
17 Jul 2020 Reviewed Reviewer Report
27 Jul 2020 Reviewed Reviewer Report
Resubmission - Version 2
4 Sep 2020 Submitted Manuscript version 2
3 Nov 2020 Author responded Author comments - Oliviero Marinelli
4 Oct 2020 Reviewed Reviewer Report
18 Oct 2020 Reviewed Reviewer Report
Resubmission - Version 3
3 Nov 2020 Submitted Manuscript version 3
Publishing
6 Nov 2020 Editorially accepted
19 Nov 2020 Article published 10.1186/s12885-020-07619-1

You can find further information about peer review here.

Back to article page